argenx SE (NASDAQ:ARGX) Shares Acquired by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC grew its position in shares of argenx SE (NASDAQ:ARGX - Free Report) by 8.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 109,490 shares of the company's stock after purchasing an additional 8,840 shares during the quarter. TimesSquare Capital Management LLC owned approximately 0.18% of argenx worth $59,352,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in ARGX. Price T Rowe Associates Inc. MD boosted its stake in shares of argenx by 49.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company's stock worth $2,167,235,000 after buying an additional 1,830,651 shares during the period. Janus Henderson Group PLC boosted its stake in shares of argenx by 24.8% during the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company's stock worth $872,690,000 after buying an additional 439,889 shares during the period. Avoro Capital Advisors LLC boosted its stake in shares of argenx by 0.3% during the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company's stock worth $487,609,000 after buying an additional 3,900 shares during the period. Clearbridge Investments LLC lifted its position in argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company's stock valued at $265,535,000 after purchasing an additional 21,189 shares during the period. Finally, Sei Investments Co. lifted its position in argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company's stock valued at $164,079,000 after purchasing an additional 50,477 shares during the period. Hedge funds and other institutional investors own 60.32% of the company's stock.

argenx Price Performance

ARGX stock traded up $4.56 during midday trading on Friday, hitting $596.00. The stock had a trading volume of 180,949 shares, compared to its average volume of 240,714. The firm has a market cap of $35.64 billion, a PE ratio of -677.27 and a beta of 0.61. argenx SE has a 12-month low of $327.73 and a 12-month high of $611.22. The company's 50-day moving average price is $547.05 and its 200 day moving average price is $474.44.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analysts' expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period in the previous year, the company earned ($1.25) EPS. As a group, sell-side analysts anticipate that argenx SE will post 2.2 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ARGX. Truist Financial raised their price objective on shares of argenx from $540.00 to $660.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. raised their price objective on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research report on Monday, November 4th. Citigroup raised their price objective on shares of argenx from $512.00 to $635.00 and gave the company a "buy" rating in a research report on Thursday, October 17th. Robert W. Baird downgraded shares of argenx from an "outperform" rating to a "neutral" rating and raised their price objective for the company from $515.00 to $650.00 in a research report on Friday, November 1st. Finally, Baird R W downgraded shares of argenx from a "strong-buy" rating to a "hold" rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $615.50.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.